BIP
IMI

Brandes Investment Partners’s Intermolecular, Inc. IMI Stock Holding History

Brandes Investment Partners’s Portfolio IMI Stock Details IMI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-37,500
Closed -$51K – 165
2017
Q4 		$51K Buy
+37,500
New +$45.1K ﹤0.01% 154

Other funds holding IMI

RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SPM
Symmetry Peak Management Radnor, Pennsylvania $359M AUM 146.87% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
HK
Horizon Kinetics New York $3.06B AUM 5.37% 1-Year Est. Return

Brandes Investment Partners's IMI Position: Q1 2018 in Review

Brandes Investment Partners sold out of Intermolecular, Inc. (IMI) in Q1 2018, closing a stake of 37,500 shares — an estimated $51K sold.

Brandes Investment Partners first reported a position in IMI in Q4 2017 and held it in 1 quarter. The position peaked at $51K in Q4 2017. 26 funds tracked by Wall St. Rank hold IMI as of Q1 2018.

  • Brandes Investment Partners reported no remaining Intermolecular, Inc. position as of Q1 2018 after selling out during the quarter.
  • Brandes Investment Partners sold 37,500 Intermolecular, Inc. shares in Q1 2018, an estimated $51K.
  • Brandes Investment Partners first reported a position in Intermolecular, Inc. in Q4 2017 and held it in 1 quarter.
  • Brandes Investment Partners's Intermolecular, Inc. position peaked at $51K in Q4 2017.
  • 26 funds tracked by Wall St. Rank held Intermolecular, Inc. as of Q1 2018.

Based on Brandes Investment Partners's 13F filing for Q1 2018, filed 15 May 2018.